Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.43 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.43 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18330020 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL18330110 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL4693326 | 0.84 | HTR2C (0.52) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL24087403 | 0.81 | MEN1 (0.46) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL21946047 | 0.81 | MEN1 (0.46) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL15878021 | 0.79 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL15878020 | 0.79 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL15894487 | 0.79 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL15878306 | 0.79 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL15878023 | 0.79 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12049465-B2 | Tricyclic compounds and their use as phosphodiesterase inhibitors | PFIZER INC. (US) | 2024-07-30 | — | — | US | disclosed |
| CN-107787322-B | Tricyclic compounds and their use as phosphodiesterase inhibitors | 辉瑞大药厂 | 2023-07-07 | — | — | CN | disclosed |
| US-20230146535-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230146535-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230146535-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230002386-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-20230002386-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-11472805-B2 | Tricyclic compounds and their use as phosphodiesterase inhibitors | PFIZER, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| EP-3766885-B1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3766885-B1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3766885-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Pfizer Inc (US) | 2021-01-20 | — | — | EP | disclosed |
| EP-3766885-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Pfizer Inc (US) | 2021-01-20 | — | — | EP | disclosed |
| EP-3310784-B1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS. | PFIZER (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-3310784-B1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS. | PFIZER (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20190263816-A1 | Tricyclic Compounds And Their Use As Phosphodiesterase Inhibitors | PFIZER INC. (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190263816-A1 | Tricyclic Compounds And Their Use As Phosphodiesterase Inhibitors | PFIZER INC. (US) | 2019-08-29 | — | — | US | disclosed |
| EP-3310784-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Pfizer Inc (US) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016203347-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016203347-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12049465-B2 | Tricyclic compounds and their use as phosphodiesterase inhibitors | PDE3B, PDE3A, PDE5A | SMN1; SMN2 3416/4885NPC1 2305/4885RAB9A 1378/4885 |
| US-20230146535-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE5A | SMN1; SMN2 3416/4885NPC1 2305/4885RAB9A 1378/4885 |
| US-11472805-B2 | Tricyclic compounds and their use as phosphodiesterase inhibitors | PDE3B, PDE3A, PDE5A | SMN1; SMN2 3416/4885NPC1 2305/4885RAB9A 1378/4885 |
| US-20190263816-A1 | Tricyclic Compounds And Their Use As Phosphodiesterase Inhibitors | PDE3B, PDE3A, PDE5A | SMN1; SMN2 3416/4885NPC1 2305/4885RAB9A 1378/4885 |
| US-20230002386-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE5A | SMN1; SMN2 3416/4885NPC1 2305/4885RAB9A 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.